Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S, Stelljes M, Bargou RC, Goebeler M, Wessiepe D, Degenhard E, Gökbuget N, Klinger M.

Author information

¹Amgen Research (Munich) GmbH, Munich, Germany.
²1] Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany [2] Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Würzburg, Germany.
³Amgen Inc., Thousand Oaks, CA, USA.
⁴Medical Department III, University Ulm, Ulm, Germany.
⁵Medical Department II, City Hospital and University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany.
⁶Bone Marrow Transplantation Center, University Münster, Münster, Germany.
⁷Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Würzburg, Germany.
⁸Metronomia GmbH, Munich, Germany.
⁹Center of Internal Medicine, J.W. Goethe University, Frankfurt, Germany.

PMID: 25192414, PMCID: PMC4183773, Free PMC Article
Blood Cancer J. 2014 Sep 5;4:244. doi: 10.1038/bcj.2014.64.

No abstract available.